Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.R Motzer, Manuela Schmidinger, Daniel Yick Chin Heng et al.|Journal of Clinical Oncology|2026Cited by 4
Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.B Venugopal, Toni K. Choueiri, R Motzer et al.|Journal of Clinical Oncology|2026Cited by 0